Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference61 articles.
1. Chronic myeloid leukemia: current treatment options;Goldman;Blood,2001
2. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylamino-pyrimidine derivative;Buchdunger;Cancer Res,1996
3. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives;Zimmermann;Bioorg Med Chem Lett,1997
4. ARG tyrosine kinase activity is inhibited by STI571;Okuda;Blood,2001
5. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity;Konopa;Cell,1984
Cited by 302 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. BCR‐ABL Inhibitors;Molecules Engineered Against Oncogenic Proteins and Cancer;2023-09-08
2. ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1;2023-07-25
3. Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia;Medicinal Chemistry Research;2023-02-02
4. Novel design of dual-action Pt(iv) anticancer pro-drugs based on cisplatin and derivatives of the tyrosine kinase inhibitors imatinib and nilotinib;Dalton Transactions;2023
5. Targeted therapy;Medicines for Cancer;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3